{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T17:44:30Z","timestamp":1767980670210,"version":"3.49.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,8]]},"DOI":"10.7759\/cureus.59938","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T06:40:03Z","timestamp":1715236803000},"source":"Crossref","is-referenced-by-count":3,"title":["Extremely Longitudinally Extensive Transverse Myelitis in a Patient With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease"],"prefix":"10.7759","author":[{"given":"So","family":"Okubo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Kakumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Tsujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyosuke","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Satake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsushi","family":"Toda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2011.176","article-title":"Longitudinal extensive transverse myelitis--it's not all neuromyelitis optica","volume":"7","author":"Trebst C","year":"2011","unstructured":"Trebst C, Raab P, Voss EV, Rommer P, Abu-Mugheisib M, Zettl UK, Stangel M. Longitudinal extensive transverse myelitis--it's not all neuromyelitis optica. Nat Rev Neurol. 2011, 7:688-98. 10.1038\/nrneurol.2011.176","journal-title":"Nat Rev Neurol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13968","article-title":"Longitudinally extensive transverse myelitis: a retrospective study differentiating neuromyelitis optica spectrum disorder from other etiologies","volume":"13","author":"Paudel S","year":"2021","unstructured":"Paudel S, Nepal G, Guragain S, et al.. Longitudinally extensive transverse myelitis: a retrospective study differentiating neuromyelitis optica spectrum disorder from other etiologies. Cureus. 2021, 13:e13968. 10.7759\/cureus.13968","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102491","article-title":"Complete spinal cord involvement from neuromyelitis optica spectrum disorder in an adult female with anti-synthetase syndrome","volume":"46","author":"Wang ZY","year":"2020","unstructured":"Wang ZY, Guo JJ, Wang M, Wei XJ, Jiang ZZ, Yu XF. Complete spinal cord involvement from neuromyelitis optica spectrum disorder in an adult female with anti-synthetase syndrome. Mult Scler Relat Disord. 2020, 46:102491. 10.1016\/j.msard.2020.102491","journal-title":"Mult Scler Relat Disord"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-014-0224-x","article-title":"Influenza-associated MOG antibody-positive longitudinally extensive transverse myelitis: a case report","volume":"14","author":"Amano H","year":"2014","unstructured":"Amano H, Miyamoto N, Shimura H, et al.. Influenza-associated MOG antibody-positive longitudinally extensive transverse myelitis: a case report. BMC Neurol. 2014, 14:224. 10.1186\/s12883-014-0224-x","journal-title":"BMC Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.5692\/clinicalneurol.cn-001290","article-title":"Longitudinally extensive transverse myelitis involving fifteen vertebral bodies positive for anti-myelin oligodendrocyte glycoprotein (MOG) antibody: a case report (Article in Japanese)","volume":"59","author":"Imai T","year":"2019","unstructured":"Imai T, Shibata S, Shinohara K, Sakurai K, Horiuchi M, Hasegawa Y. Longitudinally extensive transverse myelitis involving fifteen vertebral bodies positive for anti-myelin oligodendrocyte glycoprotein (MOG) antibody: a case report (Article in Japanese). Rinsho Shinkeigaku. 2019, 59:375-8. 10.5692\/clinicalneurol.cn-001290","journal-title":"Rinsho Shinkeigaku"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1068227","article-title":"Post-COVID-19 longitudinally extensive transverse myelitis with myelin oligodendrocyte glycoprotein antibodies","volume":"2022","author":"Yang E","year":"2022","unstructured":"Yang E, Husein A, Martinez-Perez J, Li T. Post-COVID-19 longitudinally extensive transverse myelitis with myelin oligodendrocyte glycoprotein antibodies. Case Rep Neurol Med. 2022, 2022:1068227. 10.1155\/2022\/1068227","journal-title":"Case Rep Neurol Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.12732","article-title":"Comparison of clinical outcomes of transverse myelitis among adults with myelin oligodendrocyte glycoprotein antibody vs aquaporin-4 antibody disease","volume":"2","author":"Mariano R","year":"2019","unstructured":"Mariano R, Messina S, Kumar K, Kuker W, Leite MI, Palace J. Comparison of clinical outcomes of transverse myelitis among adults with myelin oligodendrocyte glycoprotein antibody vs aquaporin-4 antibody disease. JAMA Netw Open. 2019, 2:e1912732. 10.1001\/jamanetworkopen.2019.12732","journal-title":"JAMA Netw Open"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree BAC","year":"2019","unstructured":"Cree BAC, Bennett JL, Kim HJ, et al.. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet. 2019, 394:1352-63. 10.1016\/S0140-6736(19)31817-3","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock SJ","year":"2023","unstructured":"Pittock SJ, Barnett M, Bennett JL, et al.. Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Ann Neurol. 2023, 93:1053-68. 10.1002\/ana.26626","journal-title":"Ann Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock SJ","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K, et al.. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019, 381:614-25. 10.1056\/NEJMoa1900866","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura T","year":"2019","unstructured":"Yamamura T, Kleiter I, Fujihara K, et al.. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med. 2019, 381:2114-24. 10.1056\/NEJMoa1901747","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis optica spectrum disorder","volume":"387","author":"Wingerchuk DM","year":"2022","unstructured":"Wingerchuk DM, Lucchinetti CF. Neuromyelitis optica spectrum disorder. N Engl J Med. 2022, 387:631-9. 10.1056\/NEJMra1904655","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519849511","article-title":"Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: a retrospective multicentric study","volume":"26","author":"Ciron J","year":"2020","unstructured":"Ciron J, Cobo-Calvo A, Audoin B, et al.. Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: a retrospective multicentric study. Mult Scler. 2020, 26:936-44. 10.1177\/1352458519849511","journal-title":"Mult Scler"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk M","year":"2017","unstructured":"Jurynczyk M, Messina S, Woodhall MR, et al.. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain. 2017, 140:3128-38. 10.1093\/brain\/awx276","journal-title":"Brain"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/252221-extremely-longitudinally-extensive-transverse-myelitis-in-a-patient-with-myelin-oligodendrocyte-glycoprotein-antibody-associated-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T06:40:05Z","timestamp":1715236805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/252221-extremely-longitudinally-extensive-transverse-myelitis-in-a-patient-with-myelin-oligodendrocyte-glycoprotein-antibody-associated-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,8]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.59938","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,8]]}}}